Roche has announced the launch of the Roche Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus in Allston which will further strengthen the long-standing partnership in areas such as disease biology, engineering and Artificial Intelligence / Machine Learning.
The Roche Genentech Innovation Center Boston will serve as Roche’s Cardiovascular, Renal and Metabolism (CVRM) hub, establishing a significant end-to-end R&D presence in CVRM. It will also support some of Roche’s and Genentech’s efforts in AI and data science to accelerate drug discovery and development. The laboratories will be equipped for advanced research, and over time the centre could employ up to 500 people.
Roche CEO, Thomas Schinecker, said: “Our new innovation centre builds upon our long-standing collaboration with Harvard and enables us to leverage the exceptional talent in the Boston area. By investing in a new Cardiovascular, Renal and Metabolism centre of excellence, along with data science and AI capabilities at this strategic location, we aim to accelerate Roche’s and Genentech`s research efforts and leverage the Boston innovation ecosystem. Roche has a significant presence in the US and this new centre is one of a number of research and manufacturing investments that Roche is making in the US through Genentech and Diagnostics.”
